> top > docs > PubMed:12626384 > annotations

PubMed:12626384 JSONTXT

Annnotations TAB JSON ListView MergeView

Glycan-Motif

Id Subject Object Predicate Lexical cue
T1 991-1002 https://glytoucan.org/Structures/Glycans/G81533KY denotes sialic acid
T2 1007-1014 https://glytoucan.org/Structures/Glycans/G70323CJ denotes mannose
T3 1249-1256 https://glytoucan.org/Structures/Glycans/G70323CJ denotes mannose

GlyCosmos6-Glycan-Motif-Image

Id Subject Object Predicate Lexical cue image
T1 991-1002 Glycan_Motif denotes sialic acid https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G81533KY
T2 1007-1014 Glycan_Motif denotes mannose https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G70323CJ
T3 1249-1256 Glycan_Motif denotes mannose https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G70323CJ

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-127 Sentence denotes A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease.
TextSentencer_T2 128-233 Sentence denotes Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A.
TextSentencer_T3 234-411 Sentence denotes Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease.
TextSentencer_T4 412-597 Sentence denotes Both contain the same human enzyme, alpha-galactosidase A, but they are produced using different protein expression systems and have been approved for administration at different doses.
TextSentencer_T5 598-809 Sentence denotes To determine if there is recognizable biochemical basis for the different doses, we performed a comparison of the two drugs, focusing on factors that are likely to influence biological activity and availability.
TextSentencer_T6 810-924 Sentence denotes The two drugs have similar glycosylation, both in the type and location of the oligosaccharide structures present.
TextSentencer_T7 925-1153 Sentence denotes Differences in glycosylation were mainly limited to the levels of sialic acid and mannose-6-phosphate present, with Fabrazyme having a higher percentage of fully sialylated oligosaccharides and a higher level of phosphorylation.
TextSentencer_T8 1154-1322 Sentence denotes The higher levels of phosphorylated oligomannose residues correlated with increased binding to mannose-6-phosphate receptors and uptake into Fabry fibroblasts in vitro.
TextSentencer_T9 1323-1409 Sentence denotes Biodistribution studies in a mouse model of Fabry disease showed similar organ uptake.
TextSentencer_T10 1410-1566 Sentence denotes Likewise, antigenicity studies using antisera from Fabry patients demonstrated that both drugs were indistinguishable in terms of antibody cross-reactivity.
TextSentencer_T11 1567-1774 Sentence denotes Based on these studies and present knowledge regarding the influence of glycosylation on protein biodistribution and cellular uptake, the two protein preparations appear to be functionally indistinguishable.
TextSentencer_T12 1775-1896 Sentence denotes Therefore, the data from these studies provide no rationale for the use of these proteins at different therapeutic doses.
T1 0-127 Sentence denotes A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease.
T2 128-411 Sentence denotes Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease.
T3 412-597 Sentence denotes Both contain the same human enzyme, alpha-galactosidase A, but they are produced using different protein expression systems and have been approved for administration at different doses.
T4 598-809 Sentence denotes To determine if there is recognizable biochemical basis for the different doses, we performed a comparison of the two drugs, focusing on factors that are likely to influence biological activity and availability.
T5 810-924 Sentence denotes The two drugs have similar glycosylation, both in the type and location of the oligosaccharide structures present.
T6 925-1153 Sentence denotes Differences in glycosylation were mainly limited to the levels of sialic acid and mannose-6-phosphate present, with Fabrazyme having a higher percentage of fully sialylated oligosaccharides and a higher level of phosphorylation.
T7 1154-1322 Sentence denotes The higher levels of phosphorylated oligomannose residues correlated with increased binding to mannose-6-phosphate receptors and uptake into Fabry fibroblasts in vitro.
T8 1323-1409 Sentence denotes Biodistribution studies in a mouse model of Fabry disease showed similar organ uptake.
T9 1410-1566 Sentence denotes Likewise, antigenicity studies using antisera from Fabry patients demonstrated that both drugs were indistinguishable in terms of antibody cross-reactivity.
T10 1567-1774 Sentence denotes Based on these studies and present knowledge regarding the influence of glycosylation on protein biodistribution and cellular uptake, the two protein preparations appear to be functionally indistinguishable.
T11 1775-1896 Sentence denotes Therefore, the data from these studies provide no rationale for the use of these proteins at different therapeutic doses.
T1 0-127 Sentence denotes A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease.
T2 128-233 Sentence denotes Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A.
T3 234-411 Sentence denotes Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease.
T4 412-597 Sentence denotes Both contain the same human enzyme, alpha-galactosidase A, but they are produced using different protein expression systems and have been approved for administration at different doses.
T5 598-809 Sentence denotes To determine if there is recognizable biochemical basis for the different doses, we performed a comparison of the two drugs, focusing on factors that are likely to influence biological activity and availability.
T6 810-924 Sentence denotes The two drugs have similar glycosylation, both in the type and location of the oligosaccharide structures present.
T7 925-1153 Sentence denotes Differences in glycosylation were mainly limited to the levels of sialic acid and mannose-6-phosphate present, with Fabrazyme having a higher percentage of fully sialylated oligosaccharides and a higher level of phosphorylation.
T8 1154-1322 Sentence denotes The higher levels of phosphorylated oligomannose residues correlated with increased binding to mannose-6-phosphate receptors and uptake into Fabry fibroblasts in vitro.
T9 1323-1409 Sentence denotes Biodistribution studies in a mouse model of Fabry disease showed similar organ uptake.
T10 1410-1566 Sentence denotes Likewise, antigenicity studies using antisera from Fabry patients demonstrated that both drugs were indistinguishable in terms of antibody cross-reactivity.
T11 1567-1774 Sentence denotes Based on these studies and present knowledge regarding the influence of glycosylation on protein biodistribution and cellular uptake, the two protein preparations appear to be functionally indistinguishable.
T12 1775-1896 Sentence denotes Therefore, the data from these studies provide no rationale for the use of these proteins at different therapeutic doses.

GlyCosmos6-Glycan-Motif-Structure

Id Subject Object Predicate Lexical cue
T1 991-1002 https://glytoucan.org/Structures/Glycans/G81533KY denotes sialic acid
T2 1007-1014 https://glytoucan.org/Structures/Glycans/G70323CJ denotes mannose
T3 1249-1256 https://glytoucan.org/Structures/Glycans/G70323CJ denotes mannose

GlycoBiology-FMA

Id Subject Object Predicate Lexical cue
_T1 85-95 FMAID:82780 denotes glycolipid
_T2 85-95 FMAID:196773 denotes glycolipid
_T3 147-156 FMAID:63836 denotes lysosomal
_T4 147-156 FMAID:162299 denotes lysosomal
_T5 217-230 FMAID:196789 denotes galactosidase
_T6 217-230 FMAID:82794 denotes galactosidase
_T7 250-257 FMAID:67257 denotes protein
_T8 250-257 FMAID:165447 denotes protein
_T9 454-467 FMAID:196789 denotes galactosidase
_T10 454-467 FMAID:82794 denotes galactosidase
_T11 509-516 FMAID:165447 denotes protein
_T12 509-516 FMAID:67257 denotes protein
_T13 889-904 FMAID:82742 denotes oligosaccharide
_T14 889-904 FMAID:196731 denotes oligosaccharide
_T15 1007-1014 FMAID:196796 denotes mannose
_T16 1007-1014 FMAID:82801 denotes mannose
_T17 1098-1114 FMAID:196731 denotes oligosaccharides
_T18 1098-1114 FMAID:82742 denotes oligosaccharides
_T19 1249-1256 FMAID:82801 denotes mannose
_T20 1249-1256 FMAID:196796 denotes mannose
_T21 1301-1312 FMAID:162340 denotes fibroblasts
_T22 1301-1312 FMAID:63877 denotes fibroblasts
_T23 1396-1401 FMAID:166081 denotes organ
_T24 1396-1401 FMAID:67498 denotes organ
_T25 1540-1548 FMAID:167180 denotes antibody
_T26 1656-1663 FMAID:67257 denotes protein
_T27 1656-1663 FMAID:165447 denotes protein
_T28 1709-1716 FMAID:67257 denotes protein
_T29 1709-1716 FMAID:165447 denotes protein
_T30 1856-1864 FMAID:67257 denotes proteins
_T31 1856-1864 FMAID:165447 denotes proteins

uniprot-human

Id Subject Object Predicate Lexical cue
T1 211-232 http://www.uniprot.org/uniprot/P06280 denotes alpha-galactosidase A
T2 283-293 http://www.uniprot.org/uniprot/P06280 denotes agalsidase
T3 314-324 http://www.uniprot.org/uniprot/P06280 denotes agalsidase

uniprot-mouse

Id Subject Object Predicate Lexical cue
T1 211-232 http://www.uniprot.org/uniprot/P51569 denotes alpha-galactosidase A
T2 448-469 http://www.uniprot.org/uniprot/P51569 denotes alpha-galactosidase A

GlycoBiology-NCBITAXON

Id Subject Object Predicate Lexical cue
T1 294-298 http://purl.bioontology.org/ontology/NCBITAXON/3554 denotes beta
T2 294-298 http://purl.bioontology.org/ontology/NCBITAXON/158455 denotes beta
T3 1269-1278 http://purl.bioontology.org/ontology/STY/T192 denotes receptors
T4 1531-1536 http://purl.bioontology.org/ontology/NCBITAXON/62951 denotes terms

GO-BP

Id Subject Object Predicate Lexical cue
T1 96-103 http://purl.obolibrary.org/obo/GO_0051235 denotes storage
T2 157-164 http://purl.obolibrary.org/obo/GO_0051235 denotes storage
T3 96-103 http://purl.obolibrary.org/obo/GO_0035732 denotes storage
T4 157-164 http://purl.obolibrary.org/obo/GO_0035732 denotes storage
T5 211-230 http://purl.obolibrary.org/obo/GO_0004557 denotes alpha-galactosidase
T6 448-467 http://purl.obolibrary.org/obo/GO_0004557 denotes alpha-galactosidase
T7 837-850 http://purl.obolibrary.org/obo/GO_0070085 denotes glycosylation
T8 940-953 http://purl.obolibrary.org/obo/GO_0070085 denotes glycosylation
T9 1639-1652 http://purl.obolibrary.org/obo/GO_0070085 denotes glycosylation
T10 1087-1097 http://purl.obolibrary.org/obo/GO_0097503 denotes sialylated
T11 1137-1152 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T12 1175-1189 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylated
T13 1283-1289 http://purl.obolibrary.org/obo/GO_0098657 denotes uptake
T14 1402-1408 http://purl.obolibrary.org/obo/GO_0098657 denotes uptake
T15 1693-1699 http://purl.obolibrary.org/obo/GO_0098657 denotes uptake
T16 1639-1663 http://purl.obolibrary.org/obo/GO_0006486 denotes glycosylation on protein
T17 1684-1692 http://purl.obolibrary.org/obo/GO_0007349 denotes cellular

GO-MF

Id Subject Object Predicate Lexical cue
T1 1238-1245 http://purl.obolibrary.org/obo/GO_0070026 denotes binding
T2 1238-1245 http://purl.obolibrary.org/obo/GO_0003680 denotes binding
T3 1238-1245 http://purl.obolibrary.org/obo/GO_0017091 denotes binding
T4 1238-1245 http://purl.obolibrary.org/obo/GO_0005488 denotes binding
T5 1238-1256 http://purl.obolibrary.org/obo/GO_0005537 denotes binding to mannose
T6 1540-1548 http://purl.obolibrary.org/obo/GO_0003823 denotes antibody

GO-CC

Id Subject Object Predicate Lexical cue
T1 147-156 http://purl.obolibrary.org/obo/GO_0005764 denotes lysosomal

UBERON-AE

Id Subject Object Predicate Lexical cue
T1 1396-1401 http://purl.obolibrary.org/obo/UBERON_0000062 denotes organ

EDAM-topics

Id Subject Object Predicate Lexical cue
T1 18-33 http://edamontology.org/topic_0202 denotes pharmacological
T2 119-126 http://edamontology.org/topic_0634 denotes disease
T3 134-141 http://edamontology.org/topic_0634 denotes disease
T4 147-156 http://edamontology.org/topic_0616 denotes lysosomal
T5 165-172 http://edamontology.org/topic_0634 denotes disease
T6 250-257 http://edamontology.org/topic_0078 denotes protein
T7 403-410 http://edamontology.org/topic_0634 denotes disease
T8 434-439 http://edamontology.org/topic_2815 denotes human
T9 509-516 http://edamontology.org/topic_0078 denotes protein
T10 509-527 http://edamontology.org/topic_0121 denotes protein expression
T11 509-527 http://edamontology.org/topic_0108 denotes protein expression
T12 1339-1346 http://edamontology.org/topic_3678 denotes studies
T13 1373-1380 http://edamontology.org/topic_0634 denotes disease
T14 1420-1432 http://edamontology.org/topic_2830 denotes antigenicity
T15 1433-1440 http://edamontology.org/topic_3678 denotes studies
T16 1582-1589 http://edamontology.org/topic_3678 denotes studies
T17 1656-1663 http://edamontology.org/topic_0078 denotes protein
T18 1709-1716 http://edamontology.org/topic_0078 denotes protein
T19 1806-1813 http://edamontology.org/topic_3678 denotes studies
T20 1856-1864 http://edamontology.org/topic_0078 denotes proteins

EDAM-DFO

Id Subject Object Predicate Lexical cue
T1 34-44 http://edamontology.org/operation_2424 denotes comparison
T2 250-257 http://edamontology.org/format_1208 denotes protein
T3 250-257 http://edamontology.org/data_1467 denotes protein
T4 509-516 http://edamontology.org/format_1208 denotes protein
T5 509-516 http://edamontology.org/data_1467 denotes protein
T6 694-704 http://edamontology.org/operation_2424 denotes comparison
T7 905-915 http://edamontology.org/data_0883 denotes structures
T8 1203-1211 http://edamontology.org/data_1756 denotes residues
T9 1212-1222 http://edamontology.org/operation_3465 denotes correlated
T10 1476-1488 http://edamontology.org/operation_2246 denotes demonstrated
T11 1531-1536 http://edamontology.org/data_0968 denotes terms
T12 1656-1663 http://edamontology.org/data_1467 denotes protein
T13 1656-1663 http://edamontology.org/format_1208 denotes protein
T14 1709-1716 http://edamontology.org/data_1467 denotes protein
T15 1709-1716 http://edamontology.org/format_1208 denotes protein
T16 1743-1755 http://edamontology.org/operation_0004 denotes functionally
T17 1790-1794 http://edamontology.org/data_0006 denotes data
T18 1856-1864 http://edamontology.org/data_1467 denotes proteins
T19 1856-1864 http://edamontology.org/format_1208 denotes proteins
T20 1856-1867 http://edamontology.org/data_1755 denotes proteins at

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
12626384-1#83#104#gene2717 211-232 gene2717 denotes alpha-galactosidase A
12626384-1#0#13#diseaseC0002986 128-141 diseaseC0002986 denotes Fabry disease
12626384-1#19#44#diseaseC0085078 147-172 diseaseC0085078 denotes lysosomal storage disease
83#104#gene27170#13#diseaseC0002986 12626384-1#83#104#gene2717 12626384-1#0#13#diseaseC0002986 associated_with alpha-galactosidase A,Fabry disease
83#104#gene271719#44#diseaseC0085078 12626384-1#83#104#gene2717 12626384-1#19#44#diseaseC0085078 associated_with alpha-galactosidase A,lysosomal storage disease

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 1396-1401 http://purl.obolibrary.org/obo/UBERON_0000062 denotes organ

DisGeNET

Id Subject Object Predicate Lexical cue
T0 211-232 gene:2717 denotes alpha-galactosidase A
T1 128-141 disease:C0002986 denotes Fabry disease
T2 211-232 gene:2717 denotes alpha-galactosidase A
T3 147-172 disease:C0085078 denotes lysosomal storage disease
R1 T0 T1 associated_with alpha-galactosidase A,Fabry disease
R2 T2 T3 associated_with alpha-galactosidase A,lysosomal storage disease

mondo_disease

Id Subject Object Predicate Lexical cue mondo_id
T1 113-126 Disease denotes Fabry disease http://purl.obolibrary.org/obo/MONDO_0010526
T2 128-141 Disease denotes Fabry disease http://purl.obolibrary.org/obo/MONDO_0010526
T3 147-172 Disease denotes lysosomal storage disease http://purl.obolibrary.org/obo/MONDO_0002561
T4 397-410 Disease denotes Fabry disease http://purl.obolibrary.org/obo/MONDO_0010526
T5 1367-1380 Disease denotes Fabry disease http://purl.obolibrary.org/obo/MONDO_0010526

NCBITAXON

Id Subject Object Predicate Lexical cue db_id
T1 434-439 OrganismTaxon denotes human 9606
T2 1352-1357 OrganismTaxon denotes mouse 10088|10090

Anatomy-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 1301-1312 Body_part denotes fibroblasts http://purl.obolibrary.org/obo/CL_0000057
T2 1396-1401 Body_part denotes organ http://purl.obolibrary.org/obo/UBERON_0000062|http://purl.obolibrary.org/obo/UBERON_0003103

CL-cell

Id Subject Object Predicate Lexical cue cl_id
T1 1301-1312 Cell denotes fibroblasts http://purl.obolibrary.org/obo/CL:0000057